Ratings Cellebrite DI Ltd.

Equities

CLBT

IL0011794802

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
11.53 USD -0.09% Intraday chart for Cellebrite DI Ltd. +4.34% +33.14%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • With an expected P/E ratio at 72.4 and 48.53 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.

Ratings chart - Surperformance

Sector: Software

1st Jan change Capi. Investor Rating ESG Refinitiv
+33.14% 2.37B -
+11.75% 3,123B
C+
+10.06% 86.45B
B
+6.04% 78.6B
B+
-14.66% 53.98B
B+
+26.73% 48.46B
D+
-24.44% 46.78B
B-
+31.74% 46.36B
D+
+82.12% 42.36B
D+
-8.15% 25.25B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CLBT Stock
  4. Ratings Cellebrite DI Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW